TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01058538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19IL2
Description: Route: i.v. infusion (60 min) Patients will receive a minimum of 2 cycles of treatment. Each cycle is comprised of treatment on Days 1, 3 and 5 followed by a 16 days rest (1 cycle= 21 days). Patients may receive up to 4 further cycles of treatment (max. of 6 cycles in total). Patients will be initially recruited into the study in cohorts of 3 and the starting dose of L19IL2 will be 5 Mio IU IL2 equivalent. Five steps of dose escalation are planned: 5, 10, 20, 30 and 40 Mio IU IL2 equivalent). After the MTD has been established, the RD will be determined. A further 12 patients (with RCC) will receive the RD dose for a minimum of 2 cycles. For patients in the RD part of the study, patients can switch to maintenance therapy. Maintenance therapy consists of 15 Mio IU IL2 every 2 weeks. The maximum duration of the study for a patient is 12 months.
Study: NCT04084223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: An Ultrasound exam (not performed in routine care) will be performed at Baseline, 1, 3 and 6 months for protocol.~All patients will also have CRP dosage (for DAS28 assessment), RAPID-3 and PROs (performed in routine care but analyzed for the study).
Study: NCT02724228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 111
Description: BMN 111 will be administered subcutaneously daily.
Study: NCT01528449

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B.microti diagnostic blood tests
Description: the interventions/procedures are investigational diagnostic tests for B.microti (PCR and IFA).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B.microti diagnostic blood tests
Description: the interventions/procedures are investigational diagnostic tests for B.microti (PCR and IFA).
Study: NCT02385734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concentrated Growth Factor Membrane
Description: Concentrated growth factor membrane is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronally Advanced Flap
Description: Periodontal plastic surgery technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronally Advanced Flap
Description: Periodontal plastic surgery technique
Study: NCT02352441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation Intentions(II)
Description: Implementation Intention training will include:~Demonstration and practice using examples and personal goals identified at first session. Worksheets will be provided to practice IF-THEN statements to set Implementation Intentions. Additionally, at the end of each session, the participant will be instructed to perform and event based or time based task. The objective is to see if those receiving II training are more likely to carry out the assigned task than those who do not receive II training. They will also be expected to practice II at least 5 days/week using personal goals.
Study: NCT02421562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: training in hypnoanalgesia
Description: training nurses in hypnoanalgesia techniques to perform painful procedures in children followed in the outpatient hematology oncology clinic
Study: NCT03386032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational OTC Cream
Description: Investigational Over the Counter (OTC) Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as moisturizer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.05% Desonide
Description: Rx Steroid applied topically, twice daily, once in the morning and once in the evening, for 8 weeks to all atopic dermatitis lesions.~Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to whole body as body moisturizer, except atopic dermatitis lesions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Cream
Description: Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as body moisturizer.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo Cream
Description: Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as body moisturizer.
Study: NCT04508452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine-Oxaliplatin-Irinotecan-Bevacizumab Combination
Description: CAP 1,600 mg/sq.m /day (p.o. day1-10) D1-10; Oxaliplatin (OX): 68 mg/sq.m (d.i.v.) D1; Irinotecan (IRI):135 mg/sq.m (d.i.v.) D1; BEV: 5mg/kg (d.i.v.) D1; Administered every 2 weeks.
Study: NCT02239497

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral block by ultrasound and neurostimulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous analgesia
Description: Intravenous analgesia with ketoprofen, dipyrone and dexamethasone. IV morphine to rescue analgesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous analgesia
Description: Intravenous analgesia with ketoprofen, dipyrone and dexamethasone. IV morphine to rescue analgesia
Study: NCT00518635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nutropin
Description: Nutropin 0.1 mg/day self-administered once a day
Study: NCT04425902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254 200 mg
Description: GSK3640254 will be available as oral tablets at unit dose strength of 100 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg
Description: Caffeine will be available as oral tablets at unit dose strength of 200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Description: Metoprolol will be available as oral tablets at unit dose strength of 100 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Description: Montelukast will be available as oral tablets at unit dose strength of 10 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg
Description: Flurbiprofen will be available as oral tablets at unit dose strength of 100 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Description: Omeprazole will be available as oral capsules at unit dose strength of 40 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam 5 mg (2.5 mL)
Description: Midazolam will be available as syrup for oral administration at unit dose strength of 2 milligram per milliliter (mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin 0.25 mg
Description: Digoxin will be available as oral tablet at unit dose strength of 0.25 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Description: Pravastatin will be available as oral tablet at unit dose strength of 40 mg.
Study: NCT02564679

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve gastrectomy (LSG)
Description: These patients (no. 20) are assessed by clinical and psychological evaluation (auxological parameters, blood pressure and personal and family history), blood tests (liver function test's (LFT's), uric acid, lipid and gluco-insulinemic profile with oral glucose tolerance test (OGTT)), abdominal ultrasound at time of enrollment.~They are treated with laparoscopic sleeve gastrectomy associated to lifestyle intervention. Concomitantly to surgical intervention, liver biopsy is performed.~At 6 and 12 months after LSG the patients are evaluated with laboratory, clinical and echographic assessment. Moreover, one year after LSG liver biopsy is repeated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: These patients (no. 20) are assessed by clinical and psychological evaluation (auxological parameters, blood pressure and personal and family history), blood tests (liver function test's (LFT's), uric acid, lipid and gluco-insulinemic profile with oral glucose tolerance test (OGTT)), abdominal ultrasound at time of enrollment.~They are treated with lifestyle intervention. At 6 and 12 months after enrollment the patients are evaluated with laboratory, clinical and echographic assessment.
Study: NCT00676000

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interrupted vaginal closure
Description: Horizontal mattress closure of vaginal mucosa over mesh
Study: NCT00768430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single dose .5 mg/kg IV (in the vein) infused over 40 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: single dose 0.045 mg/kg IV infused over 40 minutes
Study: NCT02145325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Expanded Tregs
Study: NCT03078751

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adjuvant endocrine therapy
Description: Letrozole 2.5 mg by mouth daily, or anastrozole 1 mg by mouth daily, exemestane 25 mg by mouth daily, tamoxifen 20 mg by mouth daily, for a total duration of at least 60 months. In premenopausal women, a GnRH agonist administered every 28 days.
Study: NCT00676000

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous vaginal closure
Description: Running closure of vaginal mucosa over mesh
Study: NCT03078751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy
Description: Letrozole 2.5 mg by mouth daily, or anastrozole 1 mg by mouth daily, exemestane 25 mg by mouth daily, tamoxifen 20 mg by mouth daily, for a total duration of at least 60 months. In premenopausal women, a GnRH agonist administered every 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months).~Placebo was supplied in the form of 200 mg film-coated tablets taken by mouth.
Study: NCT02745314

Intervention type: OTHER
Intervention: Frailty measurement
Description: Frailty measurement under Fried at el criteria

Intervention type: OTHER
Intervention: Comprehensive Geriatric Assessment
Description: Multidimensional Geriatric Assessment
Study: NCT03525483

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound for renal resistivity index measurement
Description: Collection of urine over 3 hours for creatinine clearance measurement, with serum creatinine in parallel with urine collection to calculate measured creatinine clearance and estimate glomerular filtration rate Evaluation of the renal vascular resistance index in Doppler ultrasound by a resuscitator trained in the technique at the time of inclusion.~Collection of demographic, clinical and biological data for inclusion of the patient such as weight, age, sex, arterial lactatemia, arterial pH, volume status, use of diuretics, use of vasopressors, use of nephrotoxic drugs ...
Study: NCT02052609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4827 140mg SC
Description: Experimental1:KHK4827 140mg subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4827 210mg SC
Description: Experimental2:KHK4827 210mg subcutaneous injection
Study: NCT04546607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nuvastatic TM (C5OSEW5050ESA) 1000 mg
Description: Nuvastatic TM is a patented polymolecular botanical medicine made from Lanctos 75TM which is a proprietary high potency herbal standardized extract.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nuvastatic TM (C5OSEW5050ESA) 1000 mg
Description: Nuvastatic TM is a patented polymolecular botanical medicine made from Lanctos 75TM which is a proprietary high potency herbal standardized extract.
Study: NCT01296932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836826
Description: Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion.
Study: NCT04906603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta Burst Stimulation
Description: TBS will be administered three times per day and three days per week for four weeks (totaling 12 TBS intervention visits and 36 TBS intervention sessions). Each TBS intervention session will last approximately 10 minutes (stimulation parameters = 50 Hz, 3 pulses, 10 bursts, 10 second cycle time, 60 cycles, 1800 total pulses).
Study: NCT01096290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lubiprostone
Description: 24mcg BID, capsule, oral 30days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: Twice daily for 30days, oral
Study: NCT03092765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011
Description: Intravenous administration
Study: NCT00462982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Study: NCT03057262

Intervention type: DEVICE
Intervention: Repositioning splint
Description: Application of repositioning splint in the study group.
Study: NCT02975271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serlopitant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT01530685

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glycabiane
Description: 2 gelule per day for 4 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 gelules per day for 4 months
Study: NCT03092765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011
Description: Intravenous administration
Study: NCT02796027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BRIDGE
Description: BRIDGE, enhanced HIV service integration package, has three components:~1. peer driven recruitment using a Social Network Strategy (SNS) -- which has been designated as a high impact and highly effective strategy by the CDC for reaching out and engaging PWID in HIV testing~2. HCT using CTR with Rapid Testing~3. ARTAS -- a CDC case management strategy for linking HIV-positive PWID to HIV care that addresses specific barriers and gaps in HIV service delivery in NSPs
Study: NCT01915056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GA-driven Intervention
Description: For patients assigned to the treatment arm, individuals will be offered the option of completing the GA during a visit with their primary oncologist, or attending an additional visit at the multidisciplinary geriatric oncology clinic. The intervention consists of providing results of geriatric assessment in a summary to oncologists.
Study: NCT01362933

Intervention type: PROCEDURE
Intervention: VTE treatment in cancer patient description
Description: proportion of patients treated for evolutive VTE according to international recommendations
Study: NCT04133181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D guide
Description: Use of a 3D guide in endodontic surgery

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Mock guide
Description: Use of a mock guide in endodontic surgery
Study: NCT02322528

Intervention type: DRUG
Group type: OTHER
Intervention: Administration of Lotemax
Description: An FDA approved drug (Lotemax) will be administered to induce an inflammatory mediated response in both eyes.
Study: NCT03092765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous administration
Study: NCT00059891

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Study: NCT01066494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amonafide + cytarabine
Description: Amonafide 600 mg/m2 IV over 4 hours daily on days 1-5 in combination with cytarabine 200 mg/m2 IV continuous infusion (CI) daily on days 1-7
Study: NCT03465891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: 1200mg IV on day 1 of a 21-day cycle for a planned total of 17 cycles of therapy (1 year).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: 1200mg IV on day 1 of a 21-day cycle for a planned total of 17 cycles of therapy (1 year).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low- Dose, Local Radiotherapy
Description: 4Gy will be administered in 2 fractions to a single nodal site amenable to radiation as identified by the radiation oncologist on day 2 and day 3 of Cycle 1 (over the two days following to the first dose of atezolizumab ).
Study: NCT03222141

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAVR Implantation of the THV Prosthesis
Description: Patients with TAVR implantation
Study: NCT02042391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab sc
Description: All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Rituximab will be administered as a single therapeutic agent at a standard dosage of 375 mg/m2 infused intravenously at day 1. Three subsequent single therapeutic agent applications of rituximab will be administered subcutaneously at a fixed dose of 1400 mg once a week for 3 weeks at days 8, 15 and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab sc
Description: All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Rituximab will be administered as a single therapeutic agent at a standard dosage of 375 mg/m2 infused intravenously at day 1. Three subsequent single therapeutic agent applications of rituximab will be administered subcutaneously at a fixed dose of 1400 mg once a week for 3 weeks at days 8, 15 and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab sc
Description: All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Rituximab will be administered as a single therapeutic agent at a standard dosage of 375 mg/m2 infused intravenously at day 1. Three subsequent single therapeutic agent applications of rituximab will be administered subcutaneously at a fixed dose of 1400 mg once a week for 3 weeks at days 8, 15 and 22.
Study: NCT01407588

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic navigation
Description: Ablation with use of the magnetic navigation system

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation performed with manual navigation
Description: Atrial fibrillation ablation performed with manual navigation
Study: NCT02857439

Intervention type: OTHER
Group type: OTHER
Intervention: Standard diagnostic item list
Description: All consecutive patients are assessed by both examiners, according to a standardized physical examination item list.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard diagnostic item list
Description: All consecutive patients are assessed by both examiners, according to a standardized physical examination item list.
Study: NCT02938169

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: exercise
Description: * stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.~* bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this.~* walking exercise: treadmill gait with tolerable gait speed~* flexibility exercise: stretching exercise(control)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: * stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.~* bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this.~* walking exercise: treadmill gait with tolerable gait speed~* flexibility exercise: stretching exercise(control)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: * stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.~* bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this.~* walking exercise: treadmill gait with tolerable gait speed~* flexibility exercise: stretching exercise(control)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: * stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.~* bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this.~* walking exercise: treadmill gait with tolerable gait speed~* flexibility exercise: stretching exercise(control)
Study: NCT03263689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine
Description: ITM group were given 100 micrograms of preservative-free morphine in addition to the local anaesthesia (plain hyperbaric bupivacaine 10mgs) intrathecally during the spinal anaesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine
Description: ITM group were given 100 micrograms of preservative-free morphine in addition to the local anaesthesia (plain hyperbaric bupivacaine 10mgs) intrathecally during the spinal anaesthesia
Study: NCT01592149

Intervention type: OTHER
Intervention: No Drug
Description: No intervention will be given to subjects, survey of loss of appetite in patients suffering from various healthcare disorders.